目的：探讨养肝软坚丸治疗慢性乙肝肝纤维化临床疗效。方法对照组患者给予水飞蓟宾胶囊治疗，研究组给予水飞蓟宾胶囊加养肝软坚丸治疗，记录两组乙肝肝纤维化患者治疗前后肝功能指标、肝纤维化指标变化情况及不良反应发生率，将所得数据经统计学分析后获得结论。结果经不同方法治疗后两组ALT、TBIL均较前显著降低，ALB则较前显著提高，但研究组肝功能指标改善效果优于对照组（ P＜0.05）；经不同方法治疗后两组HA、LN、Ⅳ．C、PⅢP均较前显著降低，但研究组肝纤维化指标改善效果优于对照组（P＜0.05）；研究组不良反应发生率（10.87％）虽略高于对照组（不良反应发生率6.52％），但两组对比结果并无统计学意义（ P＞0.05）。结论对慢性乙肝肝纤维化患者给予水飞蓟宾胶囊加养肝软坚丸治疗可获得更为满意的临床疗效，有利于保障患者生活质量及生命安全。%Objective To discuss the clinical effect of Yanggan Ruanjian pills in the treatment of chronic hepatitis B liver fibrosis .Methods The control group was treated with silibinin capsule .The study group was given silibinin capsules and Yanggan Ruanjian pills .Before and after treatment, the liver function, liver fibrosis and adverse changes and the incidence were recorded , and the conclusions were obtained after statistical analysis .Results After two different methods of treatment , ALT and TBIL were significantly lower than before , while the ALB was significantly improved compared with the previous , but the improvement on liver function of the study group was better than that of the control group (P<0.05).After different methods of treatment, HA, LN,Ⅳ.C and PⅢP were significantly lower than before, but the improvement on study of liver fibrosis index was better than that of the control group (P <0.05).The incidence of adverse reactions of the study group (10.87%) was slightly higher than that of the control group 6.52%), but the results were not statistically significant between two groups ( P >0.05 ).Conclusion The silibinin capsules and Yanggan Ruanjian pills in the treatment of chronic liver fibrosis administered can obtain more satisfactory clinical effect , and is conducive to the protection of patients'quality of life and life safety .
展开▼
